Nature: Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors August 20, 2025 READ MORE
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition August 20, 2025 READ MORE
Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer June 16, 2025 READ MORE
A Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class Cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle June 2, 2025 READ MORE
Preclinical Data on Circle Pharma’s CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting May 27, 2025 READ MORE
CID-078, an orally bioavailable Cyclin A/B-RxL inhibitor elicits anti-tumor activity in neuroblastoma models May 27, 2025 READ MORE
Circle Pharma to present Trials in Progress poster on CID-078, a first-in-class cyclin A/B inhibitor, at the ASCO 2025 Annual Meeting May 12, 2025 READ MORE
Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated in part by disruption of the ATR/CHK1 DNA repair pathway April 29, 2025 READ MORE
Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors April 22, 2025 READ MORE
